Bryan Wahl Sells 3,341 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now directly owns 58,057 shares of the company’s stock, valued at $2,687,458.53. This represents a 5.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 20th, Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $50.11, for a total value of $154,539.24.

Tarsus Pharmaceuticals Trading Up 0.7 %

NASDAQ:TARS opened at $49.91 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The company has a market capitalization of $1.92 billion, a PE ratio of -13.10 and a beta of 1.05. The stock has a fifty day simple moving average of $48.54 and a 200-day simple moving average of $45.06.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. On average, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Toronto Dominion Bank acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $105,714,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new position in Tarsus Pharmaceuticals during the 4th quarter valued at $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Tarsus Pharmaceuticals by 18.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company’s stock valued at $3,866,000 after buying an additional 10,991 shares in the last quarter. Finally, Woodline Partners LP raised its holdings in shares of Tarsus Pharmaceuticals by 52.3% in the 4th quarter. Woodline Partners LP now owns 108,986 shares of the company’s stock worth $6,035,000 after purchasing an additional 37,417 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Oppenheimer boosted their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Barclays decreased their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Jefferies Financial Group raised their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, Guggenheim reaffirmed a “buy” rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.